Our ambition: to become a European leader in digital therapies
Created in April 2021, Ethypharm Digital Therapy (EDT) has put together a team that reflects the values of the new company: creativity, innovation and entrepreneurship built on strong pharmaceutical experience. EDT has the exclusive rights of deprexis® in United-Kingdom, France, Italy and Spain. This digital therapy is a CE-marked class I medical device developed by GAIA AG. EDT is responsible for marketing and selling deprexis® in these four European countries.